http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 03 Jun 2026 04:30:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+List/Analysts+see+a+buying+opportunity+in+this+pharma+stock/26594396.html <p>A Danish biotech company came under pressure after U.S. International Trade Commission staff issued a post-hearing brief backing a rival drugmaker in a patent dispute involving the company's achondroplasia treatment Yuviwel. </p><p>Analysts, however, said concerns surrounding the recommendation appeared overdone and maintained bullish ratings on the stock.</p><p>Ascendis Pharma was the subject of the ITC staff recommendation, which sided with BioMarin Pharmaceutical in the dispute. </p><p>BofA Securities reiterated a “buy” rating and $288 price objective, while Wolfe Research maintained an “outperform” rating and $270 price target. </p><p>The ITC staff brief recommended a limited exclusion order covering future imports of Yuviwel http://www.streetinsider.com/Hot+List/Analysts+see+a+buying+opportunity+in+this+pharma+stock/26594396.html Wed, 03 Jun 2026 04:30:00 -0400 ASND http://www.streetinsider.com/Hot+List+Pro/Analysts+see+a+buying+opportunity+in+this+pharma+stock/26594396.html <p>A Danish biotech company came under pressure after U.S. International Trade Commission staff issued a post-hearing brief backing a rival drugmaker in a patent dispute involving the company's achondroplasia treatment Yuviwel. </p><p>Analysts, however, said concerns surrounding the recommendation appeared overdone and maintained bullish ratings on the stock.</p><p>Ascendis Pharma was the subject of the ITC staff recommendation, which sided with BioMarin Pharmaceutical in the dispute. </p><p>BofA Securities reiterated a “buy” rating and $288 price objective, while Wolfe Research maintained an “outperform” rating and $270 price target. </p><p>The ITC staff brief recommended a limited exclusion order covering future imports of Yuviwel http://www.streetinsider.com/Hot+List+Pro/Analysts+see+a+buying+opportunity+in+this+pharma+stock/26594396.html Wed, 03 Jun 2026 04:30:00 -0400 ASND http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+02++Filed+by%3A+SMITH+SCOTT+THOMAS/26592086.html si-local-file:///var/storage/secattach/20260602/26592086.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+02++Filed+by%3A+SMITH+SCOTT+THOMAS/26592086.html Tue, 02 Jun 2026 16:25:00 -0400 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+02++Filed+by%3A+SMITH+SCOTT+THOMAS/26592086.html si-local-file:///var/storage/secattach/20260602/26592086.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+Jun+02++Filed+by%3A+SMITH+SCOTT+THOMAS/26592086.html Tue, 02 Jun 2026 16:25:00 -0400 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+29++Filed+by%3A+SMITH+SCOTT+THOMAS/26583673.html si-local-file:///var/storage/secattach/20260601/26583673.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+29++Filed+by%3A+SMITH+SCOTT+THOMAS/26583673.html Mon, 01 Jun 2026 16:11:00 -0400 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+29++Filed+by%3A+SMITH+SCOTT+THOMAS/26583673.html si-local-file:///var/storage/secattach/20260601/26583673.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+29++Filed+by%3A+SMITH+SCOTT+THOMAS/26583673.html Mon, 01 Jun 2026 16:11:00 -0400 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+29++Filed+by%3A+BIENAIME+JEAN+JACQUES/26583690.html si-local-file:///var/storage/secattach/20260601/26583690.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+29++Filed+by%3A+BIENAIME+JEAN+JACQUES/26583690.html Mon, 01 Jun 2026 16:11:00 -0400 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+29++Filed+by%3A+BIENAIME+JEAN+JACQUES/26583690.html si-local-file:///var/storage/secattach/20260601/26583690.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+29++Filed+by%3A+BIENAIME+JEAN+JACQUES/26583690.html Mon, 01 Jun 2026 16:11:00 -0400 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Ascendis+Pharma+AS+++++++For%3A+Mar+18++Filed+by%3A+SMITH+SCOTT+THOMAS/26583654.html si-local-file:///var/storage/secattach/20260601/26583654.html http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Ascendis+Pharma+AS+++++++For%3A+Mar+18++Filed+by%3A+SMITH+SCOTT+THOMAS/26583654.html Mon, 01 Jun 2026 16:10:00 -0400 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Ascendis+Pharma+AS+++++++For%3A+Mar+18++Filed+by%3A+SMITH+SCOTT+THOMAS/26583654.html si-local-file:///var/storage/secattach/20260601/26583654.html http://www.streetinsider.com/SEC+Filings/Form++3A++++++++Ascendis+Pharma+AS+++++++For%3A+Mar+18++Filed+by%3A+SMITH+SCOTT+THOMAS/26583654.html Mon, 01 Jun 2026 16:10:00 -0400 ASND O.05704847 http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html <p>Investing.com -- J.P. Morgan has reinstated coverage on 14 large-cap biotechnology companies, arguing the sector is entering a major inflection point as pipeline successes increasingly translate into profitable and diversified commercial businesses.</p> <p>The bank said several biotech firms are now achieving or nearing sustained profitability, supported by expanding product portfolios, strong clinical pipelines, and potential business development activity.</p> <p></p> <p data-start="477" data-end="1219">The firm assigned Overweight ratings to companies including Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Alnylam Pharmaceuticals Inc (NASDAQ:ALNY), BeOne Medicines AG DRC (NASDAQ:ONC), United Therapeutics Corporation (NASDAQ:UTHR), Insmed Inc (NASDAQ:INSM), Ascendis Pharma AS (NASDAQ:ASND), Jazz Pharmaceuticals PLC (NASDAQ:JAZZ), Ionis Pharmaceuticals Inc (NASDAQ:IONS), Biomarin Pharmaceutical Inc http://www.streetinsider.com/Investing/JPMorgan+says+large-cap+biotech+is+back+as+profits+and+pipelines+fuel+upside/26566310.html Thu, 28 May 2026 16:07:08 -0400 ALNY ASND BMRN BNTX INCY INSM IONS JAZZ MIRM ONC UTHR VRTX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+26++Filed+by%3A+BIENAIME+JEAN+JACQUES/26557791.html si-local-file:///var/storage/secattach/20260527/26557791.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+26++Filed+by%3A+BIENAIME+JEAN+JACQUES/26557791.html Wed, 27 May 2026 16:06:00 -0400 A1SN34 ASND O.05704847 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+26++Filed+by%3A+BIENAIME+JEAN+JACQUES/26557791.html si-local-file:///var/storage/secattach/20260527/26557791.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Ascendis+Pharma+AS+++++++For%3A+May+26++Filed+by%3A+BIENAIME+JEAN+JACQUES/26557791.html Wed, 27 May 2026 16:06:00 -0400 A1SN34 ASND O.05704847